Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

Eli Lilly (NYSE:LLY) stock rose 1.3% and Novo Nordisk (NYSE:NVO) shares jumped 2% Friday morning after The Washington Post ...

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers' first choice for patients with Type ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, ...

Eli Lilly is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Learn more on LLY stock here.

Eli Lilly’s blockbuster diabetes drug Mounjaro matched the ability of an older treatment to prevent major heart complications ...

While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase ...

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results ...

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro was about as good at preventing heart attacks and strokes as its older ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.